Karyopharm leaps on positive mid-stage MM trial results

May 3, 2018

Shares of Karyopharm Therapeutics (Nasdaq: KPTI) leapt 17.5% to $15.37 yesterday, after it released encouraging mid-stage data from a trial of its multiple myeloma (MM) drug candidate and said it would be seeking regulatory approval later this year.

Karyopharm reported positive top-line results from the Phase IIb STORM study evaluating the company’s lead, oral selective inhibitor of nuclear export (SINE) compound selinexor in heavily pre-treated patients with refractory multiple myeloma. Regarding the STORM study’s primary objective, oral selinexor achieved a 25.4% overall response rate (ORR), which included two complete responses (CRs) and 29 partial (PRs) or very good partial responses (VGPRs) in these patients with penta-refractory myeloma. The median duration of response (DOR), a key secondary objective, was 4.4 months. All responses were confirmed by an Independent Review Committee (IRC).